Related Experiment Video

Updated: Jul 3, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Complement factor H Y402H polymorphism, plasma concentration and risk of coronary artery disease

Qi Qian1, Zhong Chen, Genshan Ma

  • 1Clinical Medical College of Southeast University, Nanjing, 210009, People's Republic of China.

Molecular Biology Reports
|July 8, 2008
PubMed

Insights

The Complement Factor H (CFH) Y402H gene polymorphism is linked to an increased risk of early-onset coronary artery disease (CAD) in the Chinese population. This finding contributes to understanding genetic factors in CAD development.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Inflammation is a key factor in coronary artery disease (CAD).
  • Previous studies on the Complement Factor H (CFH) gene and CAD have yielded conflicting results.
  • The CFH Y402H polymorphism's role in CAD requires further investigation, particularly in diverse ethnic groups.

Purpose of the Study:

  • To investigate the association between the CFH Y402H polymorphism and CAD in a Chinese population.
  • To determine if CFH Y402H genotype influences CAD risk.
  • To analyze plasma CFH levels in relation to CAD.

Main Methods:

  • Genotyping of the CFH Y402H single nucleotide polymorphism (SNP) using ligase detection reaction.
  • Quantification of plasma CFH levels via enzyme-linked immunosorbent assay.
  • Case-control study involving 166 CAD patients and 170 controls.

Main Results:

  • No significant difference in CFH Y402H genotype frequencies was observed between overall CAD patients and controls.
  • Significant differences in C allele and C allele carrier frequencies were found in early-onset CAD cases compared to controls.
  • Carriers of the C allele for CFH Y402H exhibited a significantly higher risk of early-onset CAD (OR 4.66, P=0.02) after adjusting for clinical parameters.
  • Plasma CFH levels did not differ between CAD patients and controls.

Conclusions:

  • The CFH Y402H polymorphism is significantly associated with an increased risk of early-onset CAD in the Chinese population.
  • The C allele of the CFH Y402H polymorphism is a potential genetic risk factor for early-onset CAD.
  • Plasma CFH levels are not associated with CAD in this cohort.
Abstract

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...